Insulin resistance, blood sugar regulation, metabolic syndrome, and body composition
461 articles
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
A landmark Lancet review reveals GLP-1 receptor agonists protect the heart, kidneys, liver, and brain — reshaping how we think about metabolic medicine.
New research reveals how fatty liver disease reshapes the tumor microenvironment, potentially accelerating cancer metastasis.
A 5-year study finds bariatric surgery offers meaningful but attenuated weight loss in PWS kids versus lifestyle intervention alone.
A large real-world study finds post-transplant diabetes requiring insulin marks a high-risk metabolic phenotype with far worse graft and patient outcomes.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
A newly identified mechanism shows how omega-3 fatty acids protect aging kidneys — and why low FFAR4 receptor expression accelerates kidney disease.
New JAMA research suggests reducing dietary protein may slow kidney disease progression and improve patient outcomes.
A new framework redefines age-related insulin resistance as a systemic collapse of metabolic resilience spanning muscle, fat, brain, and more.
Blocking mTOR forces cancer cells to rewire cholesterol uptake and transport, revealing new drug targets when combined with rapamycin.
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
